Herombopag for ITP in patients age 60 and older
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a medication called Herombopag to raise platelet counts in adults aged 60 or older with immune thrombocytopenia (ITP). The goal is to see if it is safe and effective for this age group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 60 years of age or older.
- You have been diagnosed with immune thrombocytopenia (ITP) that is new, ongoing, or has lasted a while.
- Your platelet counts have been below 30 for at least two separate tests.
- Your liver, kidney, and overall health are within acceptable limits.
- You have not used a similar platelet-boosting drug in the past 2 weeks.
- You are not taking blood thinners or NSAIDs that can affect platelet function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies herombopag to raise very low platelet counts caused by chemotherapy and reduce bleeding risk. It may help people whose platelet levels stay too low even after prior standard attempts like rhTPO or IL-11.
This study tests whether a drug called hetrombopag can help your immune system stop attacking your platelets, so your platelet count stays up even after stopping the drug. It's for people with ITP who responded well to hetrombopag but want to see if they can stay in remission without it.
This trial studies whether “TPO” medicines (like eltrombopag or similar drugs) help people age 14 and older with primary immune thrombocytopenia (ITP) who did not respond well to first treatments. It may help raise platelet counts and reduce bleeding, especially when prior therapy hasn’t worked.
This trial studies avatrombopag to raise platelet counts in adults with immune thrombocytopenia (ITP) caused by autoimmune conditions. It may help reduce bleeding risk when platelet levels are very low.
This trial compares two treatment approaches for adults with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It looks at whether adding rituximab to eltrombopag helps control ITP better and more safely.
This trial tests a new platelet-raising medicine, avatrombopag, in children with ITP who have already tried eltrombopag. It aims to see if switching to avatrombopag can safely increase platelet counts and reduce bleeding.
Hear when a new Herombopag trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.